Genmab A/S (GMAB) Announces FDA Extension of sBLA Review, Submitted by Novartis (NVS), for Ofatumumab in Relapsing Multiple Sclerosis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/30/2026

1. CMCSA
2. LFTO
3. QNT
4. NVDA
5. VRDN
6. INIO
7. HONA
8. ABBV
9. HON
10. SPY

Go back to Genmab A/S (GMAB) Announces FDA Extension of sBLA Review, Submitted by Novartis (NVS), for Ofatumumab in Relapsing Multiple Sclerosis
(NASDAQ: GMAB) Delayed: 26.02 -0.1 (0.38%)
Previous Close $26.12    52 Week High $ 
Open $26.23    52 Week Low $ 
Day High $26.42    P/E N/A 
Day Low $25.97    EPS $ 
Volume 2,029,457       

NOVARTIS AG (NYSE: NVS) Delayed: 157.59 +2.18 (1.40%)
Previous Close $155.41    52 Week High $89.15 
Open $156.14    52 Week Low $69.84 
Day High $157.73    P/E N/A 
Day Low $155.79    EPS $0.00 
Volume 2,315,099